Cargando…

Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC)

Detalles Bibliográficos
Autores principales:	Tovey, Holly, Bliss, Judith, Tutt, Andrew, Morden, James, Jarman, Katy, Martin, Sue, Kernaghan, Sarah, Toms, Christy, Kilburn, Lucy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660070/ http://dx.doi.org/10.1186/1745-6215-16-S2-P150

Ejemplares similares

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
por: Sipos, O., et al.
Publicado: (2021)

TnT: T Antigen and Telomerase, an Explosive Route to Cancer
por: Ray, F. Andrew
Publicado: (2008)

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
por: Tovey, Holly, et al.
Publicado: (2023)

Analysis techniques in the presence of non-proportional hazards (PH); application to an ovarian cancer RCT with long-term follow-up
por: Morden, James, et al.
Publicado: (2015)

TnT: a set of libraries for visualizing trees and track-based annotations for the web
por: Pignatelli, Miguel
Publicado: (2016)

Cost effectiveness of a 1-hour high-sensitivity troponin-T protocol: An analysis of the RAPID-TnT trial
por: Chuang, Ming-yu Anthony, et al.
Publicado: (2021)

Investigation on Risk Stratification and the Prognostic Value of hs-TnT Combined with MMP-2 in Patients with Acute Coronary Syndrome
por: Li, Ying, et al.
Publicado: (2021)

Conducting non-commercial international clinical trials: the ICR-CTSU experience
por: Fox, Lisa, et al.
Publicado: (2017)

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
por: Judson, Ian, et al.
Publicado: (2019)

Proportional hazards regression
por: O'Quigley, John
Publicado: (2006)

Will you still need me (Ca(2+), TnT, and DHPR), will you still cleave me (calpain), when I'm 64?
por: Pinto, José Renato, et al.
Publicado: (2016)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma
por: Song, Caiping, et al.
Publicado: (2018)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Cytotoxicity of TNT and its metabolites.
por: Banerjee, H. N., et al.
Publicado: (1999)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Which Biomarker is the Best for Predicting Mortality in Incident Peritoneal Dialysis Patients: NT-ProBNP, Cardiac TnT, or hsCRP?: A Prospective Observational Study
por: Oh, Hyung Jung, et al.
Publicado: (2015)

Cystic fibrosis transmembrane conductance regulator functional evaluations in a G542X+/- IVS8Tn:T7/9 patient with acute recurrent pancreatitis
por: Caldrer, Sara, et al.
Publicado: (2019)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
por: Lv, Xing, et al.
Publicado: (2016)

Detection of TNT-derivatives with recombinant phages
por: Simonovicá, Mladen, et al.
Publicado: (2012)

Bioremediation of Explosive TNT by Trichoderma viride
por: Alothman, Zeid A., et al.
Publicado: (2020)

Tests for the proportional hazards assumption in the Cox model
por: Reiersølmoen, L, et al.
Publicado: (2001)

On hazard ratio estimators by proportional hazards models in matched-pair cohort studies
por: Shinozaki, Tomohiro, et al.
Publicado: (2017)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer
por: Ito, Tomomichi, et al.
Publicado: (2018)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer
por: Tokunaga, Megumi, et al.
Publicado: (2022)

TNT in rectal cancer may not be the new testament?
por: Glynne-Jones, Rob
Publicado: (2019)

Borderline Values of Troponin-T and High Sensitivity C-Reactive Protein Did Not Predict 2-Year Mortality in TnT Positive Chest-Pain Patients, Whereas Brain Natriuretic Peptide Did
por: Nilsen, Dennis W. T., et al.
Publicado: (2015)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Testing the proportional hazards assumption in case-cohort analysis
por: Xue, Xiaonan, et al.
Publicado: (2013)

Biased proportional hazard regression estimator in the existence of collinearity
por: Sirohi, Anu, et al.
Publicado: (2023)

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
por: Armstrong, Stephen R, et al.
Publicado: (2012)

Nonisothermal decomposition and safety parameters of HNIW/TNT cocrystal
por: Zhang, Jiao-Qiang, et al.
Publicado: (2018)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
por: Howell, Sacha J., et al.
Publicado: (2020)

Race, mental health, and evictions filings in Memphis, TN, USA
por: Melton-Fant, Courtnee, et al.
Publicado: (2022)

Survival analysis: coping with non proportional hazards in randomized trials
por: Royston, Patrick, et al.
Publicado: (2011)

On the proportional hazards model for occupational and environmental case-control analyses
por: Gauvin, Héloïse, et al.
Publicado: (2013)

Goodness‐of‐fit tests in proportional hazards models with random effects
por: González‐Manteiga, Wenceslao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i9k99bofupth4ao1th58b3rtgj